Healthcare >> CEO Interviews >> October 5, 2000
DR. GARO H. ARMEN is the Founding Chairman and Chief Executive Officer
of Antigenics, Inc. Dr. Armen currently serves as a Director of Elan
Corporation plc. Dr. Armen also serves as the Managing General Partner
of Armen Partners, LP, an investment partnership specializing in public
and private healthcare investments. In addition to portfolio management,
Dr. Armen has provided investment banking and advisory services to the
healthcare and chemical industries. As the strategic architect, Dr.
Armen originated and structured the merger transaction between Immunex
Corporation and Lederle Oncology, a division of American Cyanamid,
serving as an advisor to both Immunex and American Cyanamid. Prior to
founding Armen Partners, LP, Dr. Armen served as a Senior Vice President
of Research at Dean Witter Reynolds, Inc. from 1986 to 1989, leading a
team of professionals specialized in the chemical and pharmaceutical
industries that provided research, investment banking and merchant
banking services. Dr. Armen's investment banking clients included
American Cyanamid Corporation, Borden Chemicals and Plastics, Elan
Corporation Plc, Forest Laboratories, Immunex Corporation, Ivax
Corporation, Key Pharmaceuticals, Lyphomed, Inc. and Vista Chemicals.
Dr. Armen graduated with a BA in Chemistry from Queens College and
received a PhD in Physical Chemistry from the Graduate Center of the
City University of New York. Following the receipt of his PhD, Dr. Armen
was appointed Research Fellow at Brookhaven National Laboratory. Profile
Dr. Armen: The company was founded in 1994 and our science is based on
immunology. Basically what we do is have the best tools, we
